Previous Close | 106.89 |
Open | 106.64 |
Bid | 106.80 x 800 |
Ask | 107.69 x 800 |
Day's Range | 106.14 - 107.46 |
52 Week Range | 89.67 - 121.64 |
Volume | |
Avg. Volume | 5,831,382 |
Market Cap | 185.474B |
Beta (5Y Monthly) | 0.74 |
PE Ratio (TTM) | 33.29 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.20 (2.06%) |
Ex-Dividend Date | Apr 12, 2024 |
1y Target Est | N/A |
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows the recent recommendation of the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA, whose vote confirmed 13 to 1, with 0 abstention that the benefi